Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Why now
Thesis: Early-stage antiviral program, speculative for micro-cap
Catalyst to watch: FDA pathway feedback or non-dilutive funding secured
Main risk: No clinical data yet, high failure odds
Why it matters
Early-stage antiviral program with no clinical data yet; speculative for a micro-cap biotech.
Details
Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility CAMBRIDGE, Mass., Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering...
Sources
- prnewswire · 2026-09-22 11:30 UTC